https://www.urticariaknowledgecenter.novartis.com/ 2021-04-23T16:12:07+00:00 1.00 https://www.urticariaknowledgecenter.novartis.com/AAAAI/aaaai.html 2021-04-21T08:14:06+00:00 0.80 https://www.urticariaknowledgecenter.novartis.com/EAACI/eaaci.html 2021-04-21T08:16:17+00:00 0.80 https://www.urticariaknowledgecenter.novartis.com/ISPOR_HTAI/ispor.html 2021-04-21T08:16:17+00:00 0.80 https://www.urticariaknowledgecenter.novartis.com/EADV/eadv.html 2021-04-21T08:14:07+00:00 0.80 https://www.urticariaknowledgecenter.novartis.com/ACAAI/acaai.html 2021-04-21T08:14:07+00:00 0.80 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/guf.html 2021-04-21T08:14:07+00:00 0.80 https://www.urticariaknowledgecenter.novartis.com/index.html 2021-04-23T16:12:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Moderate-to-severe%20CSU_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Ligelizumab%20retreatment%20achieves_poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Long-term%20ligelizumab%20treatment_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Ligelizumab%20in%20CSU_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Ligelizumab%20is%20effective%20in%20CSU_oral%20presentation.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Fast%20and%20complete%20symptom%20_oral%20presentation.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Sleep-interference%20and_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Complete%20CSU%20control%20with_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Quality-of-Life%20correlates_poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202020/GUF%202020_Exploratory%20multivariate%20analysis_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/UCARE%202019/UCARE%202019_More%20Patients%20Treated%20with%20Ligelizumab_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/UCARE%202019/UCARE%202019_Ligelizumab%20Achieves%20Sustained%20Control_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/UCARE%202019/UCARE%202019_Ligelizumab%20Reduces%20Rescue_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/UCARE%202019/UCARE%202019_Ligelizumab%20Re-treatment%20is%20Highly_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/UCARE%202019/UCARE%202019_Ligelizumab%20is%20Well%20Tolerated_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/UCARE%202019/UCARE%202019_Results%20from%20the%20Phase%202b%20Study_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/UCARE%202019/UCARE%202019_Study%20Design%20and%20Rationale_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/UCARE%202019/UCARE%202019_Dose-finding%20Phase%202%20Study_Poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202018/GUF%202018_High%20Burden%20of%20CSU_%20poster.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202018/GUF%202018_Next%20generation%20anti-IgE_Oral%20Presentation.pdf 2021-04-21T08:14:07+00:00 0.64 https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/GUF%202018/GUF%202018_Ligelizumab%20vesus%20omalizumab_Poster.pdf 2021-04-21T08:14:07+00:00 0.64